The yet-to-be-named entity will draw on the partners' respective resources in synthetic biology and plant and agricultural products.
The Series A round included investments from Illumina Ventures, Merck KGaA's M Ventures, Sofinnova Partners, Kurma Partners, and Idinvest Partners.
The two companies will work in tandem to provide customers worldwide with access to genes up to 70 kilobases in length.
The collection will be made available by BioBricks at no cost to the research community.
Agilent filed a lawsuit against Twist nearly a year ago, alleging that Twist Cofounder and CEO Emily LeProust had stolen DNA oligonucleotide synthesis technology.
Through the deal, Ginkgo has picked up Gen9's manufacturing platform and suite of proprietary technologies, software, and informatics tools for DNA synthesis and assembly.
The company intends to use the proceeds of the round to advance its proprietary enzymatic DNA synthesis technology called EcoDNA.
The company is hoping to find a niche among customers who want the quality of high-throughput oligonucleotide synthesis but smaller order volumes.
The DNA foundries have been funded through an £18 million ($23.5 million) investment from the BBSRC and should all be fully operational by next year.
Gen9's arrangement with renewable products firm Amyris comes about two months after it launched an access program for its low-cost DNA synthesis services.
The Jackson Laboratory has filed a complaint accusing Nanjing University of breeding and re-selling its mouse models, the Hartford Courant reports.
Oxford researchers are turning to virtual reality to visualize genes and regulatory elements, Phys.org says.
In Science this week: neutrophils rely on microRNA to protect against lung inflammation, and more.
China is moving forward with plans to sequence a million citizens, the Wall Street Journal reports.